Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
Wien Klin Wochenschr
; 2023 Aug 03.
Article
em En
| MEDLINE
| ID: mdl-37535134
ABSTRACT
Since 1979 Austrian children and adolescents with acute lymphoblastic leukemia (ALL) have been treated according to protocols of the Berlin-Frankfurt-Münster (BFM) study group. The Associazione Italiana di Ematologia e Oncologia Pediatrica and BFM (AIEOP-BFM) ALL 2000 study was designed to prospectively study patient stratification into three risk groups using minimal residual disease (MRD) on two time points during the patient's early disease course. The MRD levels were monitored by detection of clone-specific rearrangements of the immunoglobulin and Tcell receptor genes applying a quantitative polymerase chain reaction-based technique. The 7year event-free survival (EFS) and overall survival rates for all 608 Austrian patients treated between June 1999 and December 2009 within the AIEOP-BFM 2000 study were 84⯱ 2% and 91⯱ 1%, respectively, with a median observation time of 6.58 years. Event-free survival for patients with precursor Bcell and Tcell ALL were 84⯱ 2% (nâ¯= 521) and 84⯱ 4% (nâ¯= 87; pâ¯= 0.460), respectively. The MRD assessment was feasible in 94% of the patients and allowed the definition of precursor Bcell ALL patients with a low, intermediate or high risk of relapse even on top of clinically relevant subgroups. A similar finding with respect to MRD relevance in TALL patients was not possible due to the small number of patients and events. Since this pivotal international AIEOP-BFM ALL 2000 trial, molecular response to treatment has been continuously used with additional refinements to stratify patients into different risk groups in all successive trials of the AIEOP-BFM ALL study group.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Etiology_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Wien Klin Wochenschr
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Áustria